RxDoctor Payments Data

John Thalken, MD

Internal Medicine · Douglas, WYNPI 1912007212

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in WY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,382in general payments, 2019–2025

Across 89 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$268
  • AstraZeneca$209
  • Lilly USA, LLC$151
  • Sanofi-aventis U.S. LLC$149
  • Amgen$139
  • AbbVie$111
  • plus $355 from 10 others

What the payments were for

  • Food & beverage$1,382100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,382 in reported general payments places this provider in the 90th percentile of 101 internal medicine providers in Wyoming.

See all internal medicine providers in Wyoming

Medicare billing

Part B allowed, 2024
$8,926
Medicare patients
63
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$34,960
EntrestoSacubitril/Valsartan38$14,661
FarxigaDapagliflozin Propanediol13$6,160
Synjardy XrEmpagliflozin/Metformin Hcl24$3,699
Potassium Chloride105$2,612
Levothyroxine Sodium139$2,000
Gabapentin72$1,889
Atorvastatin Calcium90$1,441
Duloxetine Hcl24$1,393
Furosemide187$1,263
Pantoprazole Sodium65$1,201
Omeprazole68$1,194
Quetiapine Fumarate51$1,062
Rosuvastatin Calcium69$1,048
Allopurinol55$952

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$34,96097 claims
NovartisEntresto$77$14,66138 claims
AstraZenecaFarxiga$209$6,16013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 101 internal medicine providers in Wyoming.

Other internal medicine in Douglas

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →